Orgenesis Inc.

Equities

ORGS

US68619K2042

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets 12:49:59 29/05/2024 am IST			5-day change	1st Jan Change
0.4602 ^USD	-4.12%		-9.76%	-8.09%

20/05	Orgenesis Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/04	North American Morning Briefing : Powell Comments, -2-	DJ

Orgenesis Inc. Confirms Vered Caplan as President and Chief Executive Officer

August 25, 2014 at 03:36 pm IST

On August 14, 2014, the Board of Directors of Orgenesis Inc. has confirmed that Ms. Vered Caplan, who has served as President and Chief Executive Officer on an interim basis since December 23, 2013, has been appointed as President and Chief Executive Officer.

Latest news about Orgenesis Inc.

Orgenesis Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
North American Morning Briefing : Powell Comments, -2-	16/04	DJ
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04	CI
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	10/04	CI
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
North American Morning Briefing : Markets Steady -2-	26/03	DJ
North American Morning Briefing : Stock Futures -2-	19/03	DJ
Orgenesis Inc. announced that it has received $2.340901 million in funding	05/03	CI
Orgenesis Inc. announced that it expects to receive $2.340901 million in funding	03/03	CI
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.	31/01	CI
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P.	24/01	CI
Alimera Sciences Appoints New CFO	03/01	MT
Earnings Flash (ORGS) ORGENESIS Reports Q3 Revenue $110,000	14/11	MT
Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
North American Morning Briefing : Investors Weigh -2-	10/11	DJ
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon	09/11	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	09/11	MT
Orgenesis Prices $1.1 Million Registered Direct Offering	08/11	MT
Orgenesis Inc. announced that it expects to receive $1.1 million in funding	08/11	CI
Orgenesis Scraps Planned Public Offering of Units Due to Market Conditions	31/23/31	MT
CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States	21/23/21	CI
Orgenesis Inc. announced that it has received $1 million in funding	31/23/31	CI
Transcript : Orgenesis Inc., Q2 2023 Earnings Call, Aug 11, 2023	11/23/11
North American Morning Briefing : Stock Futures -2-	11/23/11	DJ
Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	11/23/11	CI

Chart Orgenesis Inc.

Duration

Period

More charts

Company Profile

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Companyâs therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomeraâs services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Sector

Medical Equipment, Supplies & Distribution

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ORGENESIS INC.	-8.09%	1.64Cr
ABBOTT LABORATORIES	-7.45%	18TCr
MEDTRONIC PLC	-0.46%	11TCr
BECTON, DICKINSON AND COMPANY	-6.90%	6.61TCr
DEXCOM, INC.	+2.43%	5.07TCr
CENCORA, INC.	+5.32%	4.31TCr
HOYA CORPORATION	+3.49%	4.07TCr
METTLER-TOLEDO INTERNATIONAL, INC.	+19.83%	3.16TCr
TERUMO CORPORATION	+16.38%	2.56TCr
WEST PHARMACEUTICAL SERVICES, INC.	-7.03%	2.42TCr

Other Medical Equipment, Supplies & Distribution

Orgenesis Inc.

Equities

ORGS

US68619K2042

Medical Equipment, Supplies & Distribution

Orgenesis Inc. Confirms Vered Caplan as President and Chief Executive Officer

Latest news about Orgenesis Inc.

Chart Orgenesis Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Medical Equipment, Supplies & Distribution